阿杜卡奴单抗的医疗保险覆盖范围——对州预算的影响。 - Suppr

Medicare Coverage of Aducanumab - Implications for State Budgets.

作者信息

Sachs Rachel E, Bagley Nicholas

机构信息

From Washington University School of Law, St. Louis (R.E.S.); and University of Michigan Law School, Ann Arbor (N.B.).

出版信息

N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.

DOI:10.1056/NEJMp2115297

PMID:34797617

Abstract

摘要

相似文献

Medicare Coverage of Aducanumab - Implications for State Budgets.

N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.

N Engl J Med. 2021 Nov 25;385(22):2017-2019. doi: 10.1056/NEJMp2113679. Epub 2021 Nov 20.

Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?

JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.

Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.

Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.

The APTA electrical stimulation lawsuit and its aftermath. American Physical Therapy Association.

Adv Wound Care. 1999 Nov-Dec;12(9):472-5.

State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.

Issue Brief (Commonw Fund). 2003 Apr(627):1-12.

Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.

Food Drug Law J. 1997;52(1):99-108.

Perspectives. IGT ban, flexibility on tap for Medicaid, but what for Medicare?

Med Health. 2005 Mar;59(6 Spec no.):1, 7-8.

Medicare changes: fairer payments, delay in practice expenses.

Minn Med. 1997 Sep;80(9):35.

One pill, many prices: variation in prescription drug prices in selected government programs.

Issue Brief George Wash Univ Natl Health Policy Forum. 2005 Aug 29(807):1-20.

引用本文的文献

The Next Generation of Payment Reforms for Population Health - An Actionable Agenda for 2035 Informed by Past Gains and Ongoing Lessons.

Milbank Q. 2023 Apr;101(S1):866-892. doi: 10.1111/1468-0009.12632.

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.

Alzheimers Dement (Amst). 2022 Aug 25;14(1):e12339. doi: 10.1002/dad2.12339. eCollection 2022.

Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Drugs Aging. 2022 Jun;39(6):389-400. doi: 10.1007/s40266-022-00949-8. Epub 2022 Jun 13.

Expedited regulatory product approval in the time of COVID-19.

Ocul Surf. 2022 Oct;26:345-348. doi: 10.1016/j.jtos.2022.05.007. Epub 2022 May 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Medicare Coverage of Aducanumab - Implications for State Budgets.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Medicare Coverage of Aducanumab - Implications for State Budgets.

作者信息

机构信息

出版信息

相似文献

引用本文的文献